Mary-Katherine Hale, the Chief Commercial Officer of Myomo, Inc., has been awarded a substantial grant of 275,000 restricted stock units (RSUs). This grant, reported in a recent SEC filing, is part of an inducement strategy aimed at attracting and retaining top executive talent within the company.

The significance of this event lies not only in Hale's compensation but also in the broader implications for the orthopedic, prosthetic, and surgical appliances industry. As companies in this sector strive to secure skilled leadership, similar incentive structures may become commonplace, shaping competitive dynamics.

Background

Myomo, Inc. is a company focused on developing innovative solutions in the orthopedic, prosthetic, and surgical appliances and supplies sector. The firm operates under the Central Index Key (CIK) number 0001369290 and is incorporated in Delaware. Myomo's fiscal year ends on December 31. The company has been active in filing reports with the SEC, including a recent Form 4 on October 13, 2026, which detailed Hale's stock unit grant.

What the Filing Says

The SEC filing indicates that the grant of 275,000 RSUs was approved by the Compensation Committee of the Board of Directors. The filing states, "Represents a grant of Restricted Stock Units ('RSU's') under an inducement grant approved by the Compensation Committee of the Board of Directors in reliance of an exception granted under Section 711 of the NYSE American Company Guide." The vesting schedule for these RSUs is structured, with 100,000 units vesting after six months, 25,000 after one year, 125,000 after two years, and the remainder after three years.

Impact

This grant may affect various stakeholders, including Myomo's shareholders and employees. By aligning executive compensation with long-term performance through RSUs, the company aims to foster a culture of growth and accountability. Other companies in the orthopedic and prosthetic industry may take note of this approach as they consider their own executive compensation packages.

What's Next

The filing does not say what happens next.